Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow DTIL by emailGet an email when DTIL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DTIL, unsubscribe in one click. Privacy
📣 What DTIL Says Is Next
year-end 2026 · “Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026.”
Company press release, Jul 1, 2026 · SEC filing
second half of 2026 · “Anticipated 2026 events include presentation of preliminary Phase 1 azer-cel data in progressive multiple sclerosis in the second half of 2026 and commencement of additional exploratory studies in autoimmune diseases outside of multiple sclerosis.”
Company press release, May 5, 2026 · SEC filing
by year-end 2026 · “Initial data from multiple patients is expected by year-end 2026, including safety and early efficacy assessment based on near full-length dystrophin protein expression from muscle biopsies.”
Company press release, Mar 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full DTIL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DTIL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.